TABLE 3.

Hazard ratios (HR) for overall survival in the population with an intermediate/poor prognosis.

		Intervention [HR (95% CI)]
		CAB + NIV	AXY + PEM	LEN + PEM	NIV + IPI	SUN
Comparator	CAB + NIV		1.05 (0.61; 1.54)	0.95 (0.51; 1.46)	1.11 (0.66; 1.61)	1.62 (1.01; 2.29)
	AXY + PEM	1.01 (0.59; 1.49)		0.92 (0.58; 1.29)	1.07 (0.78; 1.37)	1.57 (1.23; 1.91)
	LEN + PEM	1.12 (0.60; 1.73)	1.13 (0.71; 1.57)		1.19 (0.79; 1.65)	1.75 (1.21; 2.32)
	NIV + IPI	0.95 (0.56; 1.37)	0.95 (0.70; 1.22)	0.87 (0.57; 1.19)		1.48 (1.24; 1.73)
	SUN	0.64 (0.40; 0.90)	0.64 (0.51; 0.79)	0.59 (0.41; 0.79)	0.68 (0.57; 0.80)

The values in each cell represent the relative treatment effect for the intervention on the top when compared to the intervention on the left. Green suggests a relative treatment benefit (light green a nonsignificant benefit, and dark green a significant benefit). Red suggests a relative treatment harm (light red a nonsignificant harm, and dark red a significant harm).AXY, axitinib; CAB, cabozantinib; IPI, ipilimumab; LEN, lenvatinib; NIV, nivolumab; PEM, pembrolizumab; SUN, sunitinib